Induction of pulmonary cytochrome P4501A1: Interactive effects of nicotine and mecamylamine

European Journal of Pharmacology

Volumn 383, Issue 3, 1999, Pages 399-403

  Iba, Michael M ^a   Fung, Jacqueline ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

Induction: Antagonism; Mecamylamine; Nicotine; Pulmonary cytochrome P4501A1

Indexed keywords

ETHOXYRESORUFIN DEETHYLASE; MECAMYLAMINE; NICOTINE; NICOTINIC RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CONVULSION; DRUG ANTAGONISM; ENZYME ACTIVITY; ENZYME INDUCTION; FEMALE; MICROSOME MEMBRANE; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; TREMOR; WESTERN BLOTTING;

EID: 0032763626     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00639-1     Document Type: Article

References (23)

1. Akin F.J., Chamberlain W.J., Chortyk O.T. Mouse skin tumorigenesis and induction of aryl hydrocarbon hydroxylase by tobacco smoke fractions. J. Natl. Cancer Inst. 4:1975;907-912.
2. Antilla S., Hietanen E., Vainio H., Camus A.-M., Gelboin H.V., Park S.S., Heikella L., Karjalainen A., Batsch H. Smoking and peripheral type of cancer are related to high levels of pulmonary cytochrome P450IA in lung cancer patients. Intl. J. Cancer. 47:1991;681-685.
3. Benowitz, N.L., 1996. Pharmacology of nicotine: addiction and therapeutics. Annu. Rev. Pharmacol. Toxicol. 36, 597-61.
4. Clarke P.B.S., Kumar R. The effects of nicotine on locomotor activity in non-tolerant and tolerant rats. Br. J. Pharmacol. 78:1983;329-337.
5. Creasy R.M., Damaj M.I., Dimen K.R., Glassco W.S., May E.L., Martin B.R. Structure-activity relationships for mecamylamine's antagonism of nicotine in the central nervous system. Med. Chem. Res. 1996;535-542.
6. Denissenko M.F., Pao A., Tang M., Pfeifer G.P. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science. 274:1996;430-432.
7. Gautier J.C., Lecoeur S., Cosme J., Perret A., Urban P., Beaume P., Pompon D. Contribution of human cytochrome P450 to benzo[a]pyrene and benzo[a]pyrene-7,8-dihydrodiol metabolism as predicted from heterologous expression in yeast. Pharmacogenetics. 6:1996;489-499.
8. Iba M.M., Bennett S., Storch A., Ghosal A., Thomas P.E. Synergistic induction of rat microsomal CYP1A1 and CYP1A2 by acetone in combination with pyridine. Cancer Letts. 74:1993;69-74.
9. Iba M.M., Scholl H., Fung J., Thomas P.E., Alam J. Induction of pulmonary CYP1A1 by nicotine. Xenobiotica. 28:1998;827-843.
10. Iba M.M., Fung J., Park Y.W., Thomas P.E., Sekowski A., Fisher H., Halladay A.K., Wagner G.C. Dose-dependent upregulation of rat pulmonary, renal and hepatic CYP1A expression by nicotine. Drug. Metab. Dispo. 1999;. (in press).
11. Tobacco smoking. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. 38:1986;. Lyon.
12. Kellerman G., Shaw C.R., Luyten-Kellerman M. Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. New Engl. J. Med. 289:1977;934-937.
13. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1961;256-275.
14. Lu Y., Grady S., Marks M.J., Picciotto M., Changeaux J.-P., Collins A.C. Pharmacological characterization of nicotine receptor-stimulated GABA release from mouse brain synaptosomes. J. Pharmacol. Exp. Ther. 287:1998;648-657.
15. McLemore T.L., Adelberg S., Liu M.C., McMahon N.A., Yu S.J., Hubbard W.C., Czerwinski M., Wood T.G., Storeg R., Lubert R.A., Eggleston J.C., Boyd M.R., Hines R.N. Expression of CYP1A1 gene in patients with lung cancer: Evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinoma. J. Natl. Cancer. Inst. 82:1990;1333-1339.
16. Nakachi K., Iami K., Hayashi S.-I., Watanabe J., Kawajiri K. Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose. Cancer Res. 51:1991;5177-5180.
17. Okey A.B., Riddick D.S., Harper P.A. The Ah receptor: Mediator of the toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and related compounds. Toxicol. Letts. 70:1994;1-22.
18. Porchet H.C., Benowitz N.L., Sheiner L.B., Copeland J.R. Apparent tolerance to the effect of nicotine results in part from distribution kinetics. J. Clin. Invest. 80:1987;1466-1471.
19. Sadar M.D., Westlind A., Blomstrand F., Andersson T.B. Induction of CYP1A1 by GABA receptor ligands. Biochem. Biophys. Res. Commun. 229:1996;231-237.
20. Santostefano M., Merchant M., Arrelano L., Morrison V., Denison M.S., Safe S. alpha-Naphthoflavone-induced CYP1A1 gene expression and cytosolic aryl hydrocarbon receptor transformation. Mol. Pharmacol. 43:1993;200-206.
21. The Health Consequences of Smoking: Nicotine and Nicotine Addiction. 1988;Government Printing Office, Washington, DC. DHHS Publication No. (PHS) 88-223-627.
22. Welch R.M., Harrison Y.E., Conney A.H., Poppers P.J., Finster M. Cigarette smoking: Stimulatory effect on metabolism of 3,4-benzpyrene by enzymes in human placenta. Science. 160:1968;541-542.
23. Yang H.-Y.L., Namkung M.J., Juchau M.R. Cytochrome-P450-dependent biotransformation of a series of phenoxazone ethers in the rat conceptus during early organogenesis. Mol. Pharmacol. 349:1988;67-73.